WEB AtriCure Names New President, Chief Executive Officer
Proven Leader, Respected Innovator and Visionary to Lead the Company's Next Chapter of Growth
Cincinnati, Ohio, USA - March 15, 2023
WEB AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in cardiac ablation technologies for the treatment of atrial fibrillation (AFib), today announced the appointment of Elizabeth Carrel as its new President, Chief Executive Officer and member of the Board of Directors, effective immediately.
Ms. Carrel is a highly respected and experienced executive with a proven track record of success in the medical device industry. She brings a blend of strategic leadership, operational expertise and a deep understanding of the challenges and opportunities facing the sector, to AtriCure.
Prior to joining AtriCure, Ms. Carrel held leadership roles at several leading medical device companies. Most recently, she was the President of Rhythm Management at Boston Scientific Corporation. In this role, she was responsible for a global business unit with over $2 billion in revenue, and led the development and commercialization of several innovative cardiac ablation technologies.
Before that, Ms. Carrel served as the Vice President of Global Marketing and Product Development at Medtronic, Inc. In this role, she was responsible for developing and executing global marketing and product development strategies for Medtronic's cardiac rhythm management business, which generated over $4 billion in revenue.
Ms. Carrel is a graduate of the University of California, Berkeley, where she earned a Bachelor of Science degree in chemical engineering. She also holds an MBA from Harvard Business School.
AtriCure's Chairman of the Board, Michael Carrel said, "We are delighted to welcome Elizabeth to AtriCure as our new President and Chief Executive Officer. Her deep understanding of the medical device industry, combined with her proven leadership skills, make her the ideal person to lead AtriCure into its next chapter of growth. Elizabeth is a visionary leader with a strong commitment to innovation, quality and patient care. We are confident that she will guide AtriCure to even greater heights in the years to come."
Ms. Carrel said, "I am honored and excited to join AtriCure as President and Chief Executive Officer. AtriCure is a pioneer in the field of cardiac ablation, and I am eager to work with our talented team to build upon the company's legacy of innovation and success. I am confident that together, we can continue to improve the lives of patients with AFib and make a significant impact on the healthcare industry."
About WEB AtriCure, Inc.
WEB AtriCure, Inc. is a leading innovator in cardiac ablation technologies for the treatment of AFib. AtriCure's mission is to improve the lives of patients with AFib by providing innovative, less invasive solutions that address the underlying cause of the condition. AtriCure's flagship product, the AtriCure Maze Procedure, is a minimally invasive surgical procedure that has been performed in over 150,000 patients worldwide. The AtriCure Maze Procedure is the only ablation procedure that has been shown to be safe and effective for all types of AFib.
For more information, please visit www.atricure.com.
Komentar